Compare ANTA & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ANTA | SWKH |
|---|---|---|
| Founded | 2022 | 1996 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Diversified Financial Services |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.5M | 205.9M |
| IPO Year | 2025 | 1999 |
| Metric | ANTA | SWKH |
|---|---|---|
| Price | $9.28 | $16.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $17.50 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 10.3K | 5.5K |
| Earning Date | 03-17-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 669.18 | 120.89 |
| EPS | 0.47 | ★ 1.85 |
| Revenue | ★ $65,033,103.00 | $40,149,000.00 |
| Revenue This Year | $69.27 | $52.93 |
| Revenue Next Year | $64.32 | N/A |
| P/E Ratio | $18.98 | ★ $9.28 |
| Revenue Growth | ★ 63.28 | 62.38 |
| 52 Week Low | $8.35 | $13.17 |
| 52 Week High | $27.72 | $20.49 |
| Indicator | ANTA | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 54.69 |
| Support Level | $8.35 | $16.73 |
| Resistance Level | $9.55 | $17.41 |
| Average True Range (ATR) | 0.51 | 0.17 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 44.00 | 82.76 |
Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.